C-peptide and combined kidney-pancreas transplantation

Bhargava, Rama; Mitsides, Nicos; Saif, Imran; MacDowall, P; Woywodt, Alexander

doi:10.1093/ndtplus/sfp132

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the proinsulin molecule, it links insulin A chain to insulin B chain. 1 C-peptide estimation is a valuable and broadly used technique for evaluating beta cell function of pancreas. 2 It was earlier considered biologically inactive molecule, but now it is identified as an indicator of insulin secretion and a useful marker of beta-cell function.…”

Section: Introductionmentioning

confidence: 99%

C-Peptide levels as a screening marker for initiating insulin therapy in type 2 diabetics.

Gul

Ali

et al. 2019

TPMJ

View full text Add to dashboard Cite

Objectives: Serum C-peptide is identified as an indicator of insulin secretion and a useful marker of beta-cell function. Clinically C-peptide is a good indicator in differentiating between type 1 and type 2 diabetes. It is the more reliable indicator of insulin secretion and beta cell function than insulin itself. In liver during first pass metabolism half of the insulin is metabolized however the hepatic clearance of C-peptide is negligible. The purpose of this study was to explore the probability of C-peptide level as an indicator or screening for initiating insulin therapy in type 2 diabetics. Study Design: Cross sectional descriptive study. Setting: The study was conducted in attached teaching hospitals Peshawar Medical College. Period: From February 2017 to July 2017. Material and Method: In the present study 45 type 2 diabetic patients were selected from the admitted patients and patients visiting outpatient departments of Mercy and Kuwait teaching Hospitals as per the inclusion and exclusion criteria and were compared with 45 non diabetic controls. Results: A total of ninety subjects who fulfilled the inclusion criteria participated in this study. Out of them 45 were diabetics (cases) and 45 were non diabetics (controls). The mean HbA1c levels of controls was 5.351±0.57% and mean among type 2 diabetics was 8.6± 1.7%. The mean of C-peptide among type 2 diabetics is 2.349± 0.73 and the mean value of C-peptide among controls is 2.529±1.060. Patients with HbA1c of 5.5-6.8 % (Good Control), 8 patients have C-peptide in lower normal range 0.1-2 ng/mL, among patients with HbA1c of 6.9-7.6% (Fair Control), 5 patients had C-peptide in the lower normal range 0.1-2 ng/ mL and among patients with HbA1c › 7.6 (Uncontrolled), 2 had C peptide in lower normal range and 30 patients had C-peptide in the upper normal range 2.1-4 ng/ mL. In our study population the type 2 diabetics have C-peptide levels in normal range. Most of the type 2 diabetics have uncontrolled diabetes as evident from their high HbA1c levels but their C-peptide levels are in upper normal ranges. This shows that these patients have intact beta cell function and the cause of their uncontrolled diabetes may be insulin resistance, poor drug compliance and lack of awareness about the disease management. To explore the probability of C-peptide level as an indicator or screening for initiating insulin therapy in type 2 diabetics. Conclusion: It is concluded that C-peptide is not a useful marker for starting insulin therapy in type 2 diabetics. However it can be used for the clinical monitoring and management of the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

C-Peptide levels as a screening marker for initiating insulin therapy in type 2 diabetics.

Gul

Ali

et al. 2019

TPMJ

View full text Add to dashboard Cite

show abstract

“…La pérdida inmunológica es un problema que aún requiere investigación. Es claro que la variable con mayor impacto en la mortalidad del paciente sometido a este tipo de intervención continúa siendo la función renal, mucho más allá de lo que ocurra con la evolución del injerto pancreático 20,27,41,[63][64][65][66][67] .…”

Section: Introductionunclassified

Trasplante simultáneo de riñón y páncreas en pacientes con diabetes mellitus de tipo 1, Clínica Fundación Valle del Lili, Cali, 2001-2013

Serrano,

Villegas,

Echeverri

et al. 2014

Rev Colomb Cir

View full text Add to dashboard Cite

Los resultados clínicos obtenidos con el trasplante simultáneo de riñón y páncreas en pacientes con diabetes mellitus de tipo 1 e insuficiencia renal terminal, permiten afirmar que esta modalidad de trasplante constituye la mejor opción de control metabólico para este grupo de población. Objetivo. Presentar los resultados clínicos en pacientes con diabetes mellitus de tipo 1 e insuficiencia renal terminal, sometidos a trasplante simultáneo de riñón y páncreas. Materiales y métodos. Del registro institucional de trasplante renal (TRENAL), que incluye 1.300 pacientes, se seleccionaron los sometidos a trasplante simultáneo de riñón y páncreas. Se hizo un análisis con estadísticas no paramétricas y se estimó la supervivencia mediante el método de Kaplan-Meier. Resultados. Entre los años 2001 y 2012, se practicaron 27 trasplantes simultáneos de riñón y páncreas. La mayoría de los individuos era de sexo masculino (59 %), con edad –al momento del trasplante– de 34 años, y un tiempo transcurrido desde el diagnóstico de diabetes mellitus de tipo 1 de 22 años. El control glucémico se logró entre las 24 y las 48 horas después de la cirugía. La supervivencia fue de 92 % al año y de 87 % a los dos años, y la del injerto pancreático, de 88 % al año, valores equiparables a los mejores resultados esperados. Conclusión. El trasplante simultáneo de riñón y páncreas constituye una alternativa terapéutica eficaz para los pacientes con diabetes mellitus de tipo 1 e insuficiencia renal terminal. El reducido número de la muestra reflejó no sólo las dificultades existentes para la obtención de donantes, sino, también, la falta de difusión y reconocimiento de posibles candidatos; de ahí la importancia de la difusión de las experiencias existentes, con el fin de facilitar el acceso a esta opción de tratamiento.

show abstract

C-peptide and combined kidney-pancreas transplantation

Cited by 2 publications

References 12 publications

C-Peptide levels as a screening marker for initiating insulin therapy in type 2 diabetics.

C-Peptide levels as a screening marker for initiating insulin therapy in type 2 diabetics.

Trasplante simultáneo de riñón y páncreas en pacientes con diabetes mellitus de tipo 1, Clínica Fundación Valle del Lili, Cali, 2001-2013

Contact Info

Product

Resources

About